Post by Ahmad Kurniawan (AK)

Excited to share our latest review in the European Journal of Nuclear Medicine and Molecular Imaging https://lnkd.in/ePsDK96E In this review, we explore how radiolabelled PARP inhibitors can deliver radiation directly to tumour DNA, with the potential to improve cancer treatment while limiting damage to healthy tissue. We discuss the current landscape of radiolabelled PARP inhibitors for targeted radionuclide therapy, including: - The biological rationale for PARP-targeted radionuclide therapy - The advantages and limitations of Auger electron-, α-, and β-emitting radionuclides. - The critical roles of ligand design, radiochemistry, dosimetry, biomarkers, and treatment strategies in advancing clinical translation. We also highlight the key challenges that remain, including improving tumour uptake, PARP specificity, optimizing dosimetry, understanding treatment response, and establishing standardized preclinical evaluation to accelerate clinical development. Many thanks to my supervisors Bart Cornelissen, Ines Farinha Antunes, Erik F.J de Vries and all co-authors and collaborators for their invaluable guidance and contributions Philip Elsinga, Nerea Delgado Mayenco.Luis Hernández Cano, Sreelakshmi Unnikrishnan. I'm excited to see how this field continues to evolve and move closer to benefiting patients. UMCG - Nuclear Medicine and Molecular Imaging Department